A longtime leader in healthcare improvement, we’re developing new ways to revolutionize the industry.
We deliver transformative solutions that power real results. See how we can help.
Optimizing Supply Chain
Maximizing Value-Based Care
Transforming healthcare is more than our objective, it’s in our DNA. We’re dedicated to ensuring better health is just the beginning.
At every level of leadership, Premier’s experts are driving healthcare forward.
Board of Directors
Premier is more than a GPO. Combining robust analytics with consulting and advocacy, we’re changing the healthcare landscape for the better.
Find Out How
Collective purchasing power lowers costs across your organization.
Intelligence plus unparalleled analytics equals data-driven solutions.
It’s only impossible until it’s not. Premier and our team of experts are transforming care delivery.
Work with Premier members to lower costs, improve quality and safety and succeed in value-based care.
A voice for better healthcare policy is a voice for you.
Working closely with our members, we’re developing products and services to solve your most complex challenges.
Lower costs, greater efficiencies and a healthier bottom line.
Proven practices that result in better outcomes.
Intersecting specialty drugs with better management and data-driven best practices.
Controlling your future with integrated care delivery practices.
More savings and ROI is a win-win.
Data diving to deliver insights you can act on.
Data, inquiry and intervention services.
Our most recent insights, articles and more, all in one place.
View Our Latest
Discover what leading healthcare providers are achieving through Premier membership.
Stay informed with our white papers, webinars and e-books.
Browse our blog for a taste of what’s new and what’s next in healthcare.
Premier’s perspectives have been solicited by nationally renowned publications. Read on.
Read Premier’s latest announcements.
Catch our policy statements and perspectives on the latest in DC.
Find what you’re looking for, fast! Select a category or topic to get to what matters to you most.
The bill provides a critical infusion of funding for the healthcare system to respond to the COVID-19 pandemic.
Nexstar Media Wire |
Premier's Soumi Saha says mass producing more of these drugs won’t be easy, especially when the active pharmaceutical ingredients come from overseas.
The Washington Post |
Premier's Soumi Saha explains the spike in demand for two antimalarial drugs now on backorder.
The Financial Times |
Premier's Soumi Saha says hospitals need treatment guidelines or protocols from the CDC, or they will rush to buy every time small studies are released.
The Wall Street Journal |
Premier weighs in on the pharmaceutical supply of two drugs that could become a frontline treatment for COVID-19.
The Washington Post |
Premier data shows a 300% increase in orders of chloroquine and a 70% boost in orders of hydroxychloroquine.
Modern Healthcare |
Orders of chloroquine spiked 3,000% in March, according to data from Premier.
Health authorities should provide clearer guidance about drugs’ usage for COVID-19, per Premier.
Premier applauded the coordinated action Congressional leaders are taking to mitigate the spread and impact of COVID-19.
Pharmacy Times |
In terms of drug reserves, Premier is working with manufacturers to understand how much is available to wholesalers, in warehouses or in transit.
Kaiser Health News |
Premier's Soumi Saha said many state laws require pharmacists to wear masks when mixing sterile compounds.
Premier and 55 organizations applaud senators for introducing to the the bill and for their bipartisan commitment to addressing drug shortages.
The bipartisan Preventing Drug Shortages Act will shed light on the true risk of shortages of essential drugs and medical supplies.
CBS New York |
With 80% of non-active pharmaceutical ingredients made in China the whole supply chain could be put at risk said Premier's Michael Alkire.
The Act helps mitigate drug shortages and develop market-based incentives to help ensure a stable supply of medications.
It’s unclear how long exports may be restricted and whether current supplies on hand will be enough to meet U.S. needs.
Creating incentives for domestic manufacturing is urgently needed to ensure a steady supply of vital drugs and medical supplies.
Premier shared results from a member survey on their supply chain concerns stemming from the spread of the coronavirus.
The Wall Street Journal |
Premier's Soumi Saha discusses the impact on drug production in China due to the coronavirus.
Premier supports the MEDS Act as a holistic and sustainable approach to eliminating drugs shortages and addressing vulnerabilities in the drug supply chain.
It's clear Congress needs to take additional steps to prevent gaps in vital medical supplies.